Mk-677 (ibutamoren)

The strongest case for MK-677 is not what it can do—it's that it actually made it into human trials. While most growth hormone secretagogues languish in rodent work, ibutamoren cleared Phase II studies in elderly populations with hip fractures and growth hormone deficiency. That doesn't make it safe or effective for research applications. It makes the gap between clinical promise and actual approval worth examining.

An Orally Active Ghrelin Mimetic That Survived Late-Stage Development

MK-677 (ibutamoren, MK-0677) belongs to a class of compounds called growth hormone secretagogues, which stimulate growth hormone release through receptor activation rather than hormone replacement. Merck developed it in the 1990s during a wave of interest in non-peptide alternatives to injectable growth hormone. The compound structure—C27H36N4O5S, molecular weight 528.7 Da—is built around a spiro-indane scaffold that confers both oral bioavailability and resistance to peptidase degradation.

Unlike GHRP-6 or Ipamorelin, which are peptides and require injection, MK-677 is a small-molecule drug candidate. It mimics the endogenous peptide hormone ghrelin, which normally signals hunger and triggers pulsatile growth hormone release from the anterior pituitary. This structural difference matters: oral activity, longer half-life, and sustained elevation rather than pulse amplification. Merck shelved late-stage development in the early 2000s despite positive efficacy signals, likely due to safety concerns and commercial viability questions.

GHS-R1a Agonism and the Growth Hormone–IGF-1 Axis

MK-677 binds to the growth hormone secretagogue receptor type 1a (GHS-R1a), a G protein-coupled receptor primarily expressed in the arcuate nucleus of the hypothalamus and somatotroph cells of the anterior pituitary. GHS-R1a is the endogenous receptor for ghrelin, a 28-amino-acid peptide secreted by gastric X/A-like cells in the stomach fundus. Ghrelin crosses the blood-brain barrier, binds GHS-R1a in the hypothalamus, and triggers release of growth hormone-releasing hormone (GHRH), which in turn stimulates growth hormone secretion from the pituitary.

MK-677 acts as a ghrelin mimetic at this receptor, but with several key pharmacodynamic differences. First, it produces sustained receptor activation rather than the physiological pulsatile pattern seen with endogenous ghrelin or peptide secretagogues. Second, plasma growth hormone elevation is dose-dependent and prolonged—single oral doses maintain elevated growth hormone for up to 24 hours. Third, because growth hormone drives hepatic production of insulin-like growth factor 1 (IGF-1), MK-677 produces secondary increases in circulating IGF-1 with a lag period corresponding to hepatic protein synthesis kinetics.

GHS-R1a is not restricted to the hypothalamic-pituitary axis. It's also expressed in the hippocampus, ventral tegmental area, pancreatic beta cells, cardiac myocytes, and skeletal muscle. In rodent models, central GHS-R1a activation increases appetite and food-seeking behavior, mediated by neuropeptide Y (NPY) and agouti-related peptide (AgRP) neurons in the arcuate nucleus. In humans, this manifests as increased hunger and appetite reported across multiple clinical trials.

Two Decades of Human Trials Showing Efficacy Without Approval

MK-677 has been tested in at least nine published Phase I and Phase II clinical trials spanning healthy young adults, elderly populations, growth hormone-deficient adults, and patients recovering from hip fractures. The body of evidence is stronger than nearly any research peptide, which makes the lack of FDA approval more notable.

A 1997 double-blind, placebo-controlled study in 24 healthy young men (mean age 27) administered single oral doses of MK-677 at 10 mg and 50 mg. Both doses increased 24-hour mean growth hormone concentrations, with the 50 mg dose producing a roughly 2-fold increase over baseline and a corresponding rise in serum IGF-1. Growth hormone pulsatility remained intact but amplitude increased. No serious adverse events occurred at either dose.

A 1999 two-month trial in 32 healthy older adults (ages 64–81) tested 25 mg daily oral MK-677 against placebo. Growth hormone and IGF-1 levels increased significantly in the treatment group—mean serum IGF-1 rose from 123 μg/L to 194 μg/L. Fat-free mass increased by an average of 1.1 kg. Fasting glucose rose modestly but significantly in treated subjects, and two participants developed mild peripheral edema. Insulin resistance, measured by HOMA-IR, increased in the MK-677 group.

A longer 12-month trial published in 2001 followed 65 older adults randomized to MK-677 25 mg daily or placebo. Growth hormone and IGF-1 remained elevated throughout the year. Lean body mass increased, fat mass decreased, and bone turnover markers suggested accelerated remodeling—but actual bone density did not change significantly. Fasting glucose increased again. The trial noted increased appetite in 28% of treated subjects versus 8% of placebo.

A 2008 trial in growth hormone-deficient adults compared MK-677 to placebo over eight weeks. Growth hormone and IGF-1 increased dose-dependently at 10 mg and 25 mg daily. Lean mass increased, but so did fasting glucose and insulin. The study noted no change in cortisol or other pituitary hormones, confirming selectivity for the growth hormone axis.

The hip fracture trial—published in 2007—enrolled 123 elderly patients recovering from hip surgery. Participants received MK-677 25 mg daily or placebo for 12 months. The primary endpoint was functional recovery and muscle strength. MK-677 increased IGF-1 and lean mass but did not improve recovery time, gait speed, or strength outcomes. It did not reduce fall risk. Discontinuation rates were higher in the treatment arm due to congestive heart failure in two patients and transient fluid retention in several others.

Across all trials, adverse events cluster around metabolic effects—increased fasting glucose, increased appetite, and insulin resistance—and fluid retention. At least one case report (published 2019) documented acute liver injury in a healthy 24-year-old man using MK-677 purchased online; liver enzymes normalized after cessation. Whether the compound was pure is unknown, but the temporal association is notable.

Dosing, Pharmacokinetics, and Practical Parameters From Published Literature

Human trials have used oral doses ranging from 10 mg to 50 mg once daily. The most common dose in efficacy trials is 25 mg daily, which reliably elevates growth hormone and IGF-1 into the upper physiological range in older adults. A single 25 mg oral dose produces detectable growth hormone elevation within 1 hour, peak levels at 2–3 hours, and sustained elevation for at least 24 hours.

Plasma half-life is approximately 4–6 hours, but the pharmacodynamic half-life—reflected in growth hormone elevation—is longer due to sustained receptor occupancy and downstream signaling. MK-677 does not require cyclic dosing; growth hormone and IGF-1 remain elevated with continuous once-daily administration over 12 months, though partial tachyphylaxis is theoretically possible.

It is orally bioavailable and does not require refrigeration, distinguishing it from peptide-based secretagogues like Sermorelin or CJC-1295 DAC. Stability data from pharmaceutical development suggest the compound is stable at room temperature in solid form for at least two years.

MK-677 does not suppress endogenous growth hormone production through negative feedback—it acts upstream of the pituitary, and growth hormone pulsatility remains detectable in treated subjects. It does not suppress the hypothalamic-pituitary-gonadal axis, and testosterone levels were unchanged in published trials.

Because it increases IGF-1, there is theoretical concern about interactions with conditions sensitive to IGF-1 signaling, including certain cancers. No clinical trial has reported tumor development, but follow-up periods are short. Diabetic or pre-diabetic populations should note the consistent finding of increased fasting glucose and insulin resistance across trials.

For research purposes only, investigators typically use 10–25 mg oral doses once daily in human-equivalent models. Rodent studies have used weight-adjusted doses equivalent to approximately 5–10 mg/kg, which translates poorly to humans due to species differences in growth hormone physiology.

FAQ

Q: Why was MK-677 never FDA-approved despite positive trial results?

Merck discontinued development in the early 2000s without publishing an official reason. The most plausible explanations are commercial rather than scientific: growth hormone replacement therapy already existed, the metabolic side effects (glucose dysregulation, fluid retention) presented regulatory risk, and the market size for cachexia or frailty indications may not have justified Phase III costs. The 2008 hip fracture trial failure—where functional outcomes did not improve despite increased lean mass—likely closed the strongest remaining indication.

Q: Does MK-677 suppress natural growth hormone production?

No. MK-677 stimulates growth hormone release through the ghrelin receptor, which acts upstream of the pituitary gland. It does not introduce exogenous growth hormone, so it does not trigger the negative feedback loop that suppresses endogenous production. Growth hormone pulsatility remains intact, and baseline growth hormone levels return to normal after cessation without evidence of rebound suppression in published trials.

Q: What distinguishes MK-677 from peptide growth hormone secretagogues?

MK-677 is a small-molecule drug with oral bioavailability and a longer duration of action. Peptides like GHRP-2 or Hexarelin amplify the amplitude of natural growth hormone pulses but are short-acting and require injection. MK-677 produces sustained 24-hour elevation rather than pulse amplification, which may explain both its efficacy and its tendency to cause metabolic side effects. The sustained receptor activation more closely mimics chronic ghrelin exposure than physiological pulsatile signaling.

Q: What is the evidence for increased cancer risk?

There is no direct evidence from clinical trials linking MK-677 to tumor development. The theoretical concern stems from elevated IGF-1, which promotes cell proliferation and has been associated with certain cancers (prostate, breast, colorectal) in epidemiological studies. However, those associations reflect endogenous IGF-1 levels over decades, not short-term pharmacological elevation. No trial has followed participants long enough to assess cancer incidence, and no animal toxicology study has shown increased tumorigenesis at equivalent doses.

Q: Why does MK-677 increase appetite?

GHS-R1a activation in the arcuate nucleus of the hypothalamus stimulates neuropeptide Y (NPY) and agouti-related peptide (AgRP) neurons, which are the primary mediators of hunger signaling. Ghrelin is often called the "hunger hormone" because it rises before meals and triggers food-seeking behavior. MK-677 mimics this signal continuously, which is why increased appetite is one of the most consistent side effects across trials—reported in roughly one-third of participants at 25 mg daily.

Disclaimer: This content is for informational and research purposes only. MK-677 is not approved for human use by the FDA and is not intended to diagnose, treat, cure, or prevent any disease. Consult a qualified healthcare provider before considering any investigational compound.